AIM ImmunoTech Inc (AIM)
0.39
-0.02
(-4.53%)
USD |
NYAM |
May 01, 16:00
0.39
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech Cash from Investing (TTM): -0.832M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.832M |
September 30, 2023 | 2.745M |
June 30, 2023 | 3.331M |
March 31, 2023 | 11.26M |
December 31, 2022 | 10.99M |
September 30, 2022 | 7.989M |
June 30, 2022 | 7.373M |
March 31, 2022 | -1.50M |
December 31, 2021 | -0.631M |
September 30, 2021 | -1.177M |
June 30, 2021 | -10.39M |
March 31, 2021 | -12.32M |
December 31, 2020 | -9.164M |
September 30, 2020 | -14.27M |
June 30, 2020 | -4.92M |
March 31, 2020 | -1.366M |
December 31, 2019 | -6.147M |
September 30, 2019 | -2.376M |
June 30, 2019 | -1.527M |
March 31, 2019 | -2.042M |
December 31, 2018 | 0.092M |
September 30, 2018 | 2.697M |
June 30, 2018 | 2.24M |
March 31, 2018 | 3.28M |
December 31, 2017 | 2.73M |
Date | Value |
---|---|
September 30, 2017 | 1.616M |
June 30, 2017 | 2.846M |
March 31, 2017 | 3.462M |
December 31, 2016 | 2.916M |
September 30, 2016 | 7.212M |
June 30, 2016 | 8.26M |
March 31, 2016 | 6.484M |
December 31, 2015 | 6.352M |
September 30, 2015 | 3.964M |
June 30, 2015 | 2.597M |
March 31, 2015 | 2.517M |
December 31, 2014 | 2.532M |
September 30, 2014 | 9.922M |
June 30, 2014 | 13.17M |
March 31, 2014 | 16.92M |
December 31, 2013 | 22.34M |
September 30, 2013 | 2.064M |
June 30, 2013 | -9.245M |
March 31, 2013 | -12.47M |
December 31, 2012 | -16.07M |
September 30, 2012 | -3.478M |
June 30, 2012 | 6.592M |
March 31, 2012 | 9.139M |
December 31, 2011 | 8.655M |
September 30, 2011 | 8.778M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-14.27M
Minimum
Sep 2020
11.26M
Maximum
Mar 2023
-1.208M
Average
-1.366M
Median
Mar 2020
Cash from Investing (TTM) Benchmarks
Perspective Therapeutics Inc | 24.37M |
Protalix BioTherapeutics Inc | -16.71M |
Electromed Inc | -1.219M |
Xtant Medical Holdings Inc | -24.78M |
Armata Pharmaceuticals Inc | -8.134M |